Aurora cannabis announces fiscal 2022 third quarter results

Increasing original target for expense savings; management now expects $150 to $170 million in annualized cost savings by h1/2023 versus stated target of $60 to $80 million reiterating adjusted ebitda profitability run rate by the end of fiscal h1 2023 remains #1 canadian lp in high margin global medical cannabis revenues; international medical revenue increased 55% from q3 2021 strong balance sheet; early repurchase of $141.4 million in convertible debt edmonton, ab , may 12, 2022 /prnewswire/ - aurora cannabis inc. (the "company" or "aurora") (nasdaq: acb) (tsx: acb), the canadian company defining the future of cannabinoids worldwide, today announced its financial and operational results for the third quarter fiscal 2022 ended march 31, 2022. "we continue to steer our differentiated global cannabis business towards long term shareholder value creation.
ACB Ratings Summary
ACB Quant Ranking